Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp

Bullboard Posts

Comment by BigShoes13on Jan 22, 2014 6:26pm

124 Views

Post# 22122732

RE:RE:NR: Shares for Services

I would disagree that it is always a good sign. I think more often then not it is not a good sign.

I find that this often happens when the company doesn't have any money and the creditor is basically forced to take shares or sue the company. So it is usually a bad sign in my opinion.

I dont think this is the case with SBM as it should have the money. Although this is over $150,000.

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity